Sunday, November 22, 2026

Funding · Durham, NC

Precision BioSciences raises $125 million

The Durham gene editing company priced a stock offering to keep funding its hepatitis B and Duchenne muscular dystrophy programs.

·

Precision BioSciences raises $125 million

Precision BioSciences, the Durham clinical stage gene editing company, announced on Nov. 5 that it priced an underwritten offering expected to bring in about $125 million in gross proceeds, before underwriting discounts, commissions and offering expenses. The offering was expected to close on or about Nov. 6.

The company sold 10,235,077 shares of common stock at $7.75 a share and, to certain investors in place of common stock, pre-funded warrants to buy up to 5,893,964 shares. New and existing investors took part, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments and Driehaus Capital Management. TD Cowen and Guggenheim Securities served as joint book-running managers.

Precision said it plans to use the net proceeds to keep developing PBGENE-HBV, its program for chronic hepatitis B, and PBGENE-DMD, its program for Duchenne muscular dystrophy, as well as for working capital and general corporate purposes.

The raise came the same day the company shared Phase 1 ELIMINATE-B data for PBGENE-HBV ahead of the AASLD Liver Meeting. Precision said it has selected a 0.4 mg/kg go-forward dose and is starting a global Phase 2 study called ELIMINATE-B2. The company builds its in vivo gene editing candidates on ARCUS, its own genome editing platform, and trades on Nasdaq as DTIL.

Share this storyXLinkedInFacebookWhatsAppEmail

About this story

By Sotwire Desk. Written by Sotwire Desk from the sources below. Not a company attestation.

Desk reportedSotwire Desk. Written by a named Sotwire editor from the sources cited below. Not a company attestation. Sotwire corrects errors publicly.

Key facts

Company
Precision BioSciences
Place
Durham, NC
Section
Funding
Announced
Record
Desk reported
Company source
Sotwire Desk
Gross proceeds
About $125 million
Price
$7.75 per share
Book-running managers
TD Cowen and Guggenheim Securities
Programs funded
PBGENE-HBV and PBGENE-DMD

Key events

  1. Offering priced
  2. Expected closing

Sources

  1. Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants · Business Wire / Precision BioSciences · accessed 2026-11-11
  2. Exhibit 99.1: Pricing press release · U.S. Securities and Exchange Commission (Precision BioSciences filing) · accessed 2026-11-11
  3. Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting 2026 · Business Wire / Precision BioSciences · accessed 2026-11-11

North Carolina business, in one useful email.

Get launches, hires, funding, and project wins from across the state, with the Triangle at the center. Each story names the company source who stood behind it.

By subscribing, you agree to receive the Sotwire newsletter. We will not sell your email address. Newsletter details.